Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Everolimus - Abbott

Drug Profile

Everolimus - Abbott

Alternative Names: Absorb; Affinitor; Affinitor Dispersible; Afinitor; Afinitor DISPERZ; Afinitor Disperz; Certican; Esprit BVS; Promus; Promus Element; Promus Premier; RAD; RAD-001; SDZ RAD; Synergy; Synergy-everolimus-eluting-stent; Votubia; Xience nano; Xience Prime; Xience V; Xience Xpedition; Zortress

Latest Information Update: 13 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis; University of Michigan Comprehensive Cancer Center
  • Developer Abbott Laboratories; Amgen; Assistance Publique Hopitaux de Paris; Boston Scientific Corporation; Dana-Farber Cancer Institute; Genentech; Hannover Medical School; Italian Trials in Medical Oncology; National Cancer Institute (USA); New York University School of Medicine; Novartis; Sarcoma Alliance for Research through Collaboration; SCRI Development Innovations; UNC Lineberger Comprehensive Cancer Center; University of California at San Francisco; University of California, Davis; University of Pittsburgh; University of Sydney; University of Texas M. D. Anderson Cancer Center; VU University Medical Center; Yale University
  • Class Antineoplastics; Macrolides; Polyenes
  • Mechanism of Action B cell inhibitors; Immunosuppressants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Astrocytoma; Angiomyolipoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angiomyolipoma; Astrocytoma; Breast cancer; Coronary artery restenosis; Heart transplant rejection; Kidney disorders; Liver transplant rejection; Neuroendocrine tumours; Partial epilepsies; Renal cell carcinoma; Renal transplant rejection
  • Phase III Autosomal dominant polycystic kidney disease; Liver cancer; Myocardial infarction
  • Phase II Brain metastases; Cognition disorders; Endometrial cancer; Endometrial hyperplasia; Germ cell and embryonal neoplasms; Glioma; Head and neck cancer; Hodgkin's disease; Meningioma; Neurofibromatoses; Neurofibromatosis 2; Non-small cell lung cancer; Pancreatic cancer; Plexiform neurofibroma; Sarcoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Bladder cancer; Colorectal cancer; Oesophageal cancer; Respiratory tract infections
  • Phase I Haematological malignancies; Solid tumours
  • No development reported Cervical cancer; Mantle-cell lymphoma; Mesothelioma; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Thyroid cancer; Tuberous sclerosis
  • Discontinued Diffuse large B cell lymphoma; Gastric cancer; Gastrointestinal stromal tumours; Pulmonary fibrosis; Rheumatoid arthritis

Most Recent Events

  • 22 Dec 2018 Boston Scientific Corporation completes the phase III EVOLVE II trial for Coronary artery restenosis in USA, Canada, Austria, Australia, Belgium, Denmark, Finland, France, Italy, Latvia, Netherlands, New Zealand, Poland, Spain, Japan and Singapore (NCT01665053)
  • 19 Oct 2018 Efficacy and adverse events data from the phase II EVERMORE trial in Renal cell carcinoma presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
  • 05 Oct 2018 University of Pennsylvania plans a phase I/II trial for Hodgkin's lymphoma (Combination therapy, Recurrent, Refractory metastatic disease) in the US (NCT03697408)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top